Lyssikatos Joseph P 4
4 · Enliven Therapeutics, Inc. · Filed Feb 10, 2026
Research Summary
AI-generated summary of this filing
Enliven (ELVN) CSO Joseph P. Lyssikatos Sells 5,000 Shares
What Happened
Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold 5,000 shares in an open‑market transaction on February 6, 2026. The weighted average sale price was $29.04 per share, for total proceeds of $145,219. This was a sale (not a purchase or option exercise).
Key Details
- Transaction date: February 6, 2026 (reported on Form 4 filed February 10, 2026). No late filing is indicated in the document.
- Transaction type/code: Sale (S), executed as multiple trades; prices ranged from $28.925 to $29.14 (weighted average $29.04).
- Shares sold: 5,000; Proceeds: $145,219.
- Shares owned after transaction: Not disclosed on this Form 4.
- Footnotes of note:
- F1: Sale executed pursuant to a Rule 10b5‑1 trading plan adopted November 15, 2024.
- F2: Multiple trades at varying prices; reporting person will provide breakdown of individual trade prices upon SEC/issuer/stockholder request.
- F3: The shares sold were held by The Lyssikatos Revocable Trust (12/15/2011), for which Lyssikatos serves as trustee.
Context
Sales under prearranged 10b5‑1 plans are common and typically pre-scheduled, so they do not necessarily indicate a change in the insider’s view of the company. For retail investors, purchases usually carry more informational weight than routine, preplanned sales.
Insider Transaction Report
Form 4
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-02-06$29.04/sh−5,000$145,219→ 740,188 total(indirect: See footnote)
Footnotes (3)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
- [F2]This transaction was executed in multiple trades at prices ranging from $28.925 to $29.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
Signature
/s/ Ben Hohl, by power of attorney|2026-02-10